Acridine carboxamide (BioDeep_00000177922)
human metabolite blood metabolite
代谢物信息卡片
化学式: C18H19N3O (293.1528044)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: CN(C)CCNC(=O)C1=C2N=C3C=CC=CC3=CC2=CC=C1
InChI: InChI=1S/C18H19N3O/c1-21(2)11-10-19-18(22)15-8-5-7-14-12-13-6-3-4-9-16(13)20-17(14)15/h3-9,12H,10-11H2,1-2H3,(H,19,22)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D004791 - Enzyme Inhibitors
同义名列表
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Azeem Saleem, Pat M Price. Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Dec; 14(24):8184-90. doi:
10.1158/1078-0432.ccr-08-1324. [PMID: 19088034] - A Saleem, E O Aboagye, J C Matthews, P M Price. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
Cancer chemotherapy and pharmacology.
2008 Apr; 61(5):865-73. doi:
10.1007/s00280-007-0552-2. [PMID: 17639391] - O Clyde Hutchinson, David R Collingridge, Henryk Barthel, Pat M Price, Eric O Aboagye. Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.
Current pharmaceutical design.
2003; 9(11):917-29. doi:
10.2174/1381612033455288. [PMID: 12678875] - S Zhou, R Chin, P Kestell, M D Tingle, J W Paxton. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
British journal of clinical pharmacology.
2001 Aug; 52(2):129-36. doi:
10.1046/j.0306-5251.2001.01438.x. [PMID: 11488768] - K O Hicks, F B Pruijn, B C Baguley, W R Wilson. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
The Journal of pharmacology and experimental therapeutics.
2001 Jun; 297(3):1088-98. doi:
NULL. [PMID: 11356933] - H S Al-Salmy. Individual variation in hepatic aldehyde oxidase activity.
IUBMB life.
2001 Apr; 51(4):249-53. doi:
10.1080/152165401753311799. [PMID: 11569919] - S Osman, G Rowlinson-Busza, S K Luthra, E O Aboagye, G D Brown, F Brady, R Myers, S A Gamage, W A Denny, B C Baguley, P M Price. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Cancer research.
2001 Apr; 61(7):2935-44. doi:
NULL. [PMID: 11306471] - A Saleem, R J Harte, J C Matthews, S Osman, F Brady, S K Luthra, G D Brown, N Bleehen, T Connors, T Jones, P M Price, E O Aboagye. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2001 Mar; 19(5):1421-9. doi:
10.1200/jco.2001.19.5.1421. [PMID: 11230487] - G J Finlay, B C Baguley. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
Cancer chemotherapy and pharmacology.
2000; 45(5):417-22. doi:
10.1007/s002800051011. [PMID: 10803926] - P C Schofield, I G Robertson, J W Paxton, M R McCrystal, B D Evans, P Kestell, B C Baguley. Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.
Cancer chemotherapy and pharmacology.
1999; 44(1):51-8. doi:
10.1007/s002800050944. [PMID: 10367749] - P Kestell, I C Dunlop, M R McCrystal, B D Evans, J W Paxton, R S Gamage, B C Baguley. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Cancer chemotherapy and pharmacology.
1999; 44(1):45-50. doi:
10.1007/s002800050943. [PMID: 10367748] - S Osman, S K Luthra, F Brady, S P Hume, G Brown, R J Harte, J C Matthews, W A Denny, B C Baguley, T Jones, P M Price. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
Cancer research.
1997 Jun; 57(11):2172-80. doi:
NULL. [PMID: 9187117] - F Brady, S K Luthra, G Brown, S Osman, R J Harte, W A Denny, B C Baguley, T Jones, P M Price. Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
1997 Apr; 48(4):487-92. doi:
10.1016/s0969-8043(96)00294-1. [PMID: 9106990] - S M Evans, I G Robertson, J W Paxton. Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit.
The Journal of pharmacy and pharmacology.
1994 Jan; 46(1):63-7. doi:
10.1111/j.2042-7158.1994.tb03722.x. [PMID: 8201529] - I G Robertson, B D Palmer, J W Paxton, T J Bland. Metabolism of the experimental antitumor agent acridine carboxamide in the mouse.
Drug metabolism and disposition: the biological fate of chemicals.
1993 May; 21(3):530-6. doi:
. [PMID: 8100511] - J W Paxton, D Young, S M Evans, I G Robertson, P Kestell. Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.
Cancer chemotherapy and pharmacology.
1993; 32(4):320-2. doi:
10.1007/bf00686179. [PMID: 8324875] - J W Paxton, D Young, I G Robertson. Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.
Cancer chemotherapy and pharmacology.
1993; 32(4):323-5. doi:
10.1007/bf00686180. [PMID: 8324876] - S M Evans, D Young, I G Robertson, J W Paxton. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
Cancer chemotherapy and pharmacology.
1992; 31(1):32-6. doi:
10.1007/bf00695991. [PMID: 1458557] - J W Paxton, D Young, S M Evans, P Kestell, I G Robertson, E M Cornford. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
Cancer chemotherapy and pharmacology.
1992; 29(5):379-84. doi:
10.1007/bf00686007. [PMID: 1551177] - D Young, P C Evans, J W Paxton. Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography.
Journal of chromatography.
1990 Jun; 528(2):385-94. doi:
10.1016/s0378-4347(00)82396-8. [PMID: 2384576]